GSK Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 май 2024 @ 23:00):

Stats
Объем за сегодня	5.94M
Средний объем	3.45M
Рыночная капитализация	87.96B
EPS	$0 ( 2024-05-01 )
Дата следующего отчета о доходах	( $1.030 ) 2024-07-24
Last Dividend	$0.340 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	15.88
ATR14	$0.0280 (0.06%)

Объем Корреляция

Длинно: -0.33 (neutral)

Кратко: 0.68 (moderate)

Signal:(52.315) Neutral

GlaxoSmithKline PLC Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции
YSAC	-0.891

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

GlaxoSmithKline PLC Корреляция - Валюта/Сырье

0.12
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.54
( weak )

-0.25
( neutral )

GlaxoSmithKline PLC Финансовые показатели

Annual	2023
Выручка:	$30.33B
Валовая прибыль:	$21.25B (70.07 %)
EPS:	$1.220

FY	2023
Выручка:	$30.33B
Валовая прибыль:	$21.25B (70.07 %)
EPS:	$1.220

FY	2022
Выручка:	$29.32B
Валовая прибыль:	$19.77B (67.42 %)
EPS:	$1.220

FY	2021
Выручка:	$34.11B
Валовая прибыль:	$22.51B (65.99 %)
EPS:	$2.19

Financial Reports:

No articles found.

GlaxoSmithKline PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.391 (N/A)	$0.317 (N/A)	$0.340 (N/A)	$0.348 (N/A)	$0.361 (N/A)	$0.340 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Sustainability Score: 9.66 - good (96.56%) | Divividend Growth Potential Score: 7.25 - Increase likely (44.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0420	1987-05-15
Last Dividend	$0.340	2023-11-16
Next Dividend	$0	N/A
Payout Date	2024-01-11
Next Payout Date	N/A
# dividends	120	--
Total Paid Out	$57.37	--
Avg. Dividend % Per Year	2.89%	--
Score	6.19	--
Div. Sustainability Score	9.66
Div.Growth Potential Score	7.25
Div. Directional Score	8.45	--

Next Divdend (Est)
(2024-06-03)

$0.335 Estimate 38.07 %

Dividend Stability

0.76 Good

Dividend Score

6.19

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.184	2.39%
1988	$0.135	1.42%
1989	$0.319	3.31%
1990	$0.468	3.63%
1991	$0.567	3.45%
1992	$0.861	2.70%
1993	$0.363	1.52%
1994	$1.027	4.86%
1995	$1.159	5.55%
1996	$1.164	4.14%
1997	$1.218	3.88%
1998	$1.148	2.39%
1999	$1.134	1.60%
2000	$2.03	3.65%
2001	$0.854	1.53%
2002	$1.889	3.79%
2003	$1.368	3.55%
2004	$1.604	3.43%
2005	$1.527	3.22%
2006	$1.738	3.41%
2007	$2.06	3.83%
2008	$2.14	4.27%
2009	$1.855	5.02%
2010	$1.998	4.65%
2011	$2.21	5.62%
2012	$2.48	5.35%
2013	$2.41	5.46%
2014	$2.65	5.02%
2015	$2.45	5.78%
2016	$2.77	6.85%
2017	$2.06	5.31%
2018	$2.16	5.85%
2019	$2.05	5.40%
2020	$2.06	4.39%
2021	$2.21	5.85%
2022	$1.680	3.85%
2023	$1.389	3.94%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.387	1.500	6.82	10.00	[0.1 - 1]
payoutRatioTTM	0.456	-1.000	5.44	-5.44	[0 - 1]
currentRatioTTM	0.885	0.800	-0.575	-0.460	[1 - 3]
quickRatioTTM	0.597	0.800	-1.192	-0.954	[0.8 - 2.5]
cashRatioTTM	0.139	1.500	-0.337	-0.505	[0.2 - 2]
debtRatioTTM	0.288	-1.500	5.21	-7.81	[0 - 0.6]
interestCoverageTTM	9.12	1.000	7.73	7.73	[3 - 30]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.035	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	1.271	-1.500	4.92	-7.37	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.330	1.330	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.24	7.24	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.386	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.514	0.800	9.91	7.93	[0.5 - 2]
Total Score				9.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	28.43	1.000	7.23	0	[1 - 100]
returnOnEquityTTM	0.387	2.50	7.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.035	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	4.21	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.456	1.500	5.44	-5.44	[0 - 1]
pegRatioTTM	0.524	1.500	9.84	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.216	1.000	7.11	0	[0.1 - 0.5]
Total Score				7.25

GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.